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INTRODUCTION
Neuropathic pain is a common and significant prob-
lem, for individuals with a spinal cord injury (SCI). The 
reported prevalence of neuropathic pain after an SCI var-
ies from 38% to 40% [1,2]. Neuropathic pain is likely to 
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Objective  To determine whether providing education about the disease pathophysiology and drug mechanisms 
and side effects, would be effective for reducing the use of pain medication while appropriately managing 
neurogenic pain in spinal cord injury (SCI) patients.
Methods  In this prospective study, 109 patients with an SCI and neuropathic pain, participated in an educational 
pain management program. This comprehensive program was specifically created, for patients with an SCI and 
neuropathic pain. It consisted of 6 sessions, including educational training, over a 6-week period.
Results  Of 109 patients, 79 (72.5%) initially took more than two types of pain medication, and this decreased 
to 36 (33.0%) after the educational pain management program was completed. The mean pain scale score and 
the number of pain medications decreased, compared to the baseline values. Compared to the non-response 
group, the response group had a shorter duration of pain onset (p=0.004), and a higher initial number of different 
medications (p<0.001) and certain types of medications.
Conclusion  This study results imply that an educational pain management program, can be a valuable 
complement to the treatment of spinal cord injured patients with neuropathic pain. Early intervention is 
important, to prevent patients from developing chronic SCI-related pain.
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persist, and it tends to worsen [3]. It has been correlated 
with a depressive mood [3-6], poorer rehabilitation out-
come [7], and lower quality of life [8,9]. Although various 
medical treatments are used, the treatment of SCI-related 
neuropathic pain remains a clinical challenge.
Various pharmacological agents such as gabapentin, 
pregabalin, and amitriptyline have been suggested for 
treating neuropathic pain. However, there is controversy 
regarding the effects of medications on SCI-related neu-
ropathic pain, due to a lack of clear evidence [10,11]. A 
pharmacologic intervention is often inadequate, result-
ing in only a reduction of 20%–30% in the pain intensi-
ty [12]. Furthermore, neuropathic pain is associated with 
polypharmacy [10,13-15], and the increased use of medi-
cations can lead to increased costs, more side effects, and 
an increased risk of fatigue as well as confused states, 
falls, and injuries [11]. High rates of polypharmacy and 
positive associations with drug-related problems in the 
population with an SCI have been reported, and medica-
tions for pain increase the risk of fatigue [16].
Therefore, there is growing interest in non-pharmaco-
logical treatments, as these can be used as an effective 
complement to pharmacological interventions to en-
hance the overall impact of pain-reliving interventions 
for individuals with an SCI [17]. In addition, since patient 
education does not require special equipment, providing 
continuous feedback alone may be effective for reducing 
the use of polypharmacy [18]. It has been suggested that 
improving and maintaining sleep states or environments 
are more effective than drug therapy or using treatment 
modalities, but scant research data is available to sub-
stantiate this.
In our study, we explored whether providing education 
about the disease pathophysiology and drug mechanisms 
and side effects would be effective, for reducing the use 
of pain medication while appropriately managing pain in 
patients with an SCI and neuropathic pain.
MATERIALS AND METHODS
Subjects
Between January 2014 and December 2014, all patients 
with an SCI admitted to the Department of Physical 
Medicine and Rehabilitation at Yonsei University Hospi-
tal were screened. Clinical data were examined, and the 
International Spinal Cord Injury Pain Classification (IS-
CIPC) was used. They were included in the study when 
they met the following inclusion criteria: (1) patients 
older than 20, (2) those with symptom onset of less than 
6 months, (3) patients with a non-progressive spinal cord 
lesion due to traumatic or non-traumatic causes, (4) 
those with neuropathic pain, as defined by the ISCIPC, 
and (5) patients with taking pain medication. Exclusion 
criteria were patients (1) with musculoskeletal pain; (2) 
concurrent, multiple bony fractures, except spine frac-
tures; (3) a previous brain injury or concurrent brain 
lesion, (4) history of neuropathic pain, and (5) previous 
neuropsychiatric disorder.
Demographic and injury-related characteristics
Subjects were assessed within 48 hours of the begin-
ning, and end of the intervention period. Subjects’ clini-
cal data, including demographic characteristics such as 
sex and age, and time since injury, were collected. The 
assessment of neurological function after SCI was per-
formed according to the International Standards for Neu-
rological Classification of Spinal Cord Injury (ISNCSCI), 
and subjects’ Neurological Level of Injury (NLI), ASIA 
impairment scale (AIS) grade, and injury etiology were 
collected.
Evaluation of neuropathic pain and the medication 
profile
According to the ISCIPC, a detailed clinical pain history 
that included onset, pain description (numbness, prick-
ing sense, etc.), course and daily variation, associated 
symptoms, and factors was investigated; additionally, 
physical examination was also conducted that involved 
confirmation by a painful response and character of the 
pain, such as allodynia, hyperalgesia, hyperalgesia, etc. 
Neuropathic pain was divided into three groups: at-level 
neuropathic pain, below-level neuropathic pain, other 
(e.g., complex regional pain syndrome) [19,20]. A reha-
bilitation doctor matched subjects’ pain drawings, which 
illustrated the worst pain site and pain severity with pain 
characteristics according to the classification. Patients 
were asked to rate their global intensity of pain using the 
visual analog scale (VAS) (0, no pain; 10, worst possible 
pain) weekly, and they maintained a pain diary; scores 
were averaged over seven days. The main outcome was 
pain at baseline and 6 weeks later.
Pain medications were classified into nine categories: 
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acetaminophen, nonsteroidal anti-inflammatory drugs 
(NSAIDs), opioids, gabapentin, pregabalin, other anti-
convulsants (such as valproic acid, etc.), tricyclic antide-
pressants (TCAs), serotonin selective reuptake inhibitors 
(SSRIs) or serotonin–norepinephrine reuptake inhibi-
tors (SNRIs), and other (such as afloqualone, etc.). Data 
on the number of different types of medications used 
at baseline and 6 weeks later (follow-up) was collected 
[21,22].
Physical and functional statuses
ASIA motor subscores (sum of the upper extremity mo-
tor score and lower extremity motor score; range, 0–100) 
and sensory subscores (light touch and pin prick; range, 
0–112, both) were assessed to evaluate physical function. 
The scores of the Functional Independence Measure 
(FIM; range, 18–126) and Spinal Cord Independence 
Measurement III mobility section (SCIM3; range, 0–100) 
were used to measure each patient’s functional status.
Evaluation of depressive mood
Depressive mood was evaluated according to the Beck 
Depression Inventory (BDI), which determines how 
much depression an individual is feeling with respect to 
the severity of the depressive symptom [23]. This scale 
consists of 21 questions, and each question is scored on a 
scale from 0–3 (range, 0–63), with a higher score indicat-
ing more severe depression [24].
Intervention
An educational pain management program was devel-
oped for patients with an SCI and neuropathic pain, and 
it consisted of a 6-week treatment program. All patients 
were assessed within 48 hours of the beginning and end 
of the intervention period. The educational pain man-
agement program consisted of weekly sessions, during 
which a physiatrist provided the following information: 
(i) the natural course of the SCI, (ii) SCI-related pain 
physiology, and (iii) types, dose, use, side effects, and 
costs of pain medication. After conducting the physical 
examination and assessing history on the initial evalua-
tion, the patients were shown the slides containing infor-
mation about (i) and (ii) for approximately 30 minutes. 
After identifying drugs that the patient was taking, the 
patients were provided information about the indica-
tions, mechanism of action, and side effects of the drug, 
using simple, descriptive handouts. Approximately 10 
minutes, the question and response for the (i), (ii), (iii) 
to once a week face-to-face were performed for 6 weeks. 
After each educational session, the patients shared feed-
back with the rehabilitation specialist who determined 
whether the medications were effective. The medications 
were considered effective if the following were achieved: 
(1) pain reduction of at least 30% or (2) the resolution 
of sleep disturbance and improvement in quality of life. 
If these outcomes were not achieved, the medications 
were determined to have no significant effects. In such 
Patients diagnosed with spinal cord injury (SCI)
(n=267)
Patients finally included in analysis
(n=109)
Failed to meet the inclusion criteria (n=140)
(1) Age < 20 years (n=31)
(2) Onset > 6 months (n=29)
(3) Progressive SCI (n=11)
(4) With or without musculoskeletal pain (n=24)
(5) Multiple bony fractures except spine fracture (n=13)
(6) Previous brain injury or concurrent with brain lesion (n=5)
(7) Previous neuropathic pain history (n=4)
(8) Previous neuropsychiatric disorder (n=1)
(9) No pain medication at initial (n=22)
Follow-up loss
(n=18)
Fig. 1. Flowchart of the subjects. A 
total 267 patients with spinal cord 
injury (SCI) were assessed from 
January 1, 2014 to December 31, 
2014. Finally, 109 patients were 
included and they were classified 
into two groups according to the 
response.
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cases, we recommended a reduction in the use of medi-
cations, based on the Beers criteria and the previously 
published studies [25,26]. After assessing the number of 
different types of medications taken at the beginning and 
end of the program as the secondary outcome, the pa-
tients who revealed reductions in the number of different 
types of medications were defined as the response group, 
whereas those who revealed no changes or an increase 
in the number of medications were defined as the non-
response group.
Statistical analysis
The general characteristics or baseline data were com-
pared between each group using the Student t-test for 
continuous variables, if the data was normally distrib-
uted. Associations between qualitative variables were 
assessed using the c2-test or Fisher exact test. Differ-
ences between the groups regarding changes in the use 
of medications were measured using paired t-tests. Using 
the variables with either statistical or clinical signifi-
cance, binary logistic regression analysis was performed 
to identify injury characteristics that influenced response 
after education. SPSS software ver. 23.0 (IBM, Armonk, 
NY, USA) was used to perform the statistical analyses. 
Statistical significance was considered when the p-value 
was less than 0.05.
RESULTS
Patients’ characteristics
Among all patients, 267 had an SCI, of whom 109 sat-
isfied the inclusion and exclusion criteria, as shown in 
Fig. 1. Seventy-five were men (68.8%), with a mean age 
of 50.6±13.9 years and a mean duration of pain onset of 
67.1±46.4 days. Sixty-nine patients (63.3%) had cervical 
SCI, with an average VAS score of 4.8±2.3. Subjects took 
an average of 2.4±1.3 types of medications. When classi-
fying subjects according to their responses, we classified 
76 subjects into the response group and 33 into the non-
response group (Fig. 1).
SCI characteristics and demographic factors associated 
with the response to education
The duration of pain onset (p=0.004) revealed a statis-










   Male 75 (68.8) 54 (71.1) 21 (63.6) 0.443
   Female 34 (31.2) 22 (28.9) 12 (36.4)
Age (yr) 50.6±13.9 50.67±13.9 49.7±14.0 0.660
Duration after onset (day) 67.1±46.4 58.7±41.9 86.3±51.0 0.004**
Neurological level of injury
   Cervical 69 (63.3) 49 (64.5) 20 (60.6) 0.624
   Thoracic 35 (32.1) 24 (31.6) 11 (33.3)
   Lumbosacral 5 (4.6) 3 (3.9) 2 (6.1)
AIS grade 
   A 37 (33.9) 27 (35.5) 10 (30.3) 0.579
   B 5 (4.6) 3 (3.9) 2 (6.1)
   C 29 (26.6) 21 (27.6) 8 (24.2)
   D 38 (34.9) 25 (32.9) 13 (39.4)
Etiology
   Traumatic 76 (69.7) 53 (69.7) 23 (69.7) 0.997
   Non-traumatic 33 (30.3) 23 (30.3) 10 (30.3)
Values are presented as mean±standard deviation or number (%).
AIS, American Spinal Injury Association impairment scale.
**p<0.01.
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tically significant correlation with the response group. 
Other injury-related characteristics did not reveal signifi-
cant differences in sex, age, NLI, the AIS grade, and etiol-
ogy between the two groups (Table 1).
Response in relation to neuropathic pain and the 
medication profile
Initial VAS scores decreased at the follow-up in the 
response and non-response groups, with no significant 
differences between the two groups. There were no sig-
nificant differences in responses to a reduction in medi-
cations, between the different VAS scores and pain types. 
An initial high number of different medications (p<0.001) 
and patients taking acetaminophen, NSAIDs, pregaba-
lin, TCAs, SSRIs, or SNRIs, and other pain medications 
revealed statistically significant associations between the 
response and non-response groups (Tables 2, 3). 










   VASinitial 4.8±2.3 4.8±2.1 4.8±2.6 0.982
   VASfollow-up 3.3±1.7 3.4±1.7 3.0±1.7 0.217
   VASchange 1.3±0.5 1.3±0.5 1.3±0.5 0.930
Pain type
   At-level 66 (60.6) 45 (59.2) 21 (63.6) 0.526
   Below-level 41 (37.6) 29 (38.2) 12 (36.4)
   Others 2 (1.8) 2 (2.6) 0 (0.0)
Number of different medicationsinitial 2.4±1.3 2.9±1.2 1.4±0.7 <0.001***
Number of medication classificationinitial
   Acetaminophen 39 (35.8) 34 (44.7) 5 (15.2) 0.001**
   NSAIDs 38 (34.9) 31 (40.8) 7 (21.2) 0.037*
   Opioids 37 (33.9) 29 (38.2) 8 (24.2) 0.144
   Gabapentin 57 (52.3) 40 (52.6) 17 (51.5) 0.916
   Pregabalin 30 (27.5) 27 (35.5) 3 (9.1) 0.001**
   Other anticonvulsants 1 (0.9) 1 (1.3) 0 (0.0) 0.512
   TCA 39 (35.8) 34 (44.7) 5 (15.2) 0.001**
   SSRI or SNRI 17 (15.6) 15 (19.7) 2 (6.1) 0.031*
   Others 8 (7.3) 8 (10.5) 0 (0.0) 0.004**
Values are presented as mean ± standard deviation or number (%).
VAS, visual analogue scale; NSAIDs, nonsteroidal anti-inflammatory drugs; TCA, tricyclic antidepressants; SSRI, sero-
tonin selective reuptake inhibitors; SNRI, serotonin–norepinephrine reuptake inhibitor. 
*p<0.05, **p<0.01, ***p<0.001.
Table 3. Changes of neuropathic pain medication profile
Initial Follow-up
Acetaminophen 39 (35.8) 9 (8.3)
NSAIDs 38 (34.9) 14 (12.8)
Opioids 37 (33.9) 9 (8.3)
Gabapentin 57 (52.3) 51 (46.8)
Pregabalin 30 (27.5) 6 (5.5)
Other anticonvulsants 1 (0.9) 0 (0.0)
TCA 39 (35.8) 31 (28.4)
SSRI or SNRI 17 (15.6) 9 (8.3)
Others 8 (7.3) 2 (1.8)
Values are presented as number (%).
NSAIDs, nonsteroidal anti-inflammatory drugs; TCA, tri-
cyclic antidepressants; SSRI, serotonin selective reuptake 
inhibitors; SNRI, serotonin–norepinephrine reuptake 
inhibitor. 
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Response in relation to the physical function score, 
functional independence status, and depressive mood
The physical function score, motor scores, and sensory 
score were not statistically significantly different between 
the two groups. Regarding subjects’ functional level, the 
FIM and SCIM3 scores were not statistically significantly 
different between the two groups (Table 4).
There were significant differences among all the groups 
for the reduction in VAS scores and increases in the mo-
tor score, sensory score, and functional score at follow-
up compared to baseline measurements. The response 
group had a significantly lower BDI score than the non-
response group (Table 5). Regression analysis revealed 
that there were no statistically significant correlations be-
tween the improvement in functional status or reduction 
in depression and the response. 
Number of different medications
Seventy-nine (72.5%) of 109 patients took more than 
two types of pain medications at initial, and this number 
decreased to 36 (33.0%) after completing the educational 
pain management program (Fig. 2). 
DISCUSSION
In the present study, providing education significantly 
reduced the number of different types of pain medica-
tions patients used. When comparing the non-response 
group to the response group, which is the group that re-
vealed a reduction in medications at the follow-up, dura-










   Motor scoreinitial 45.4±23.9 44.8±23.2 46.8±26.0 0.697
   Motor scorefollow-up 51.1±25.3 50.2±24.3 53.1±27.8 0.587
   Motor scorechange 5.7±.8.1 5.4±7.6 6.3±9.5 0.588
Light score
   Light scoreinitial 50.7±27.4 49.9±28.3 52.6±25.4 0.646
   Light scorefollow-up 54.7±28.7 54.1±30.4 56.1±24.6 0.721
   Light scorechange 3.9±10.4 4.1±10.6 3.5±9.8 0.755
Pin prick score 
   Pin prick scoreinitial 46.1±28.3 44.5±29.2 49.8±26.4 0.360
   Pin prick scorefollow-up 51.0±29.6 49.5±30.7 54.5±27.0 0.422
   Pin prick scorechange 4.9±13.8 5.0±14.5 4.7±12.5 0.933
FIM
   FIMinitial 60.9±18.7 59.9±17.9 63.5±20.5 0.359
   FIMfollow-up 72.8±23.4 73.1±23.8 72.2±22.7 0.517
   FIMchange 11.9±15.2 13.2±16.5 8.8±11.5 0.111
SCIM3
   SCIM3initial 26.2±19.1 24.6±17.2 29.8±22.6 0.190
   SCIM3follow-up 36.3±24.2 36.0±23.5 37.0±26.2 0.833
   SCIM3change 10.1±13.9 11.4±15.6 7.2±8.3 0.073
BDI
   BDIinitial 18.0±7.9 18.4±7.8 16.8±8.0 0.337
   BDIfollow-up 16.6±7.4 16.8±7.5 16.2±7.2 0.702
   BDIchange 1.3±3.5 1.6±3.8 0.6±2.5 0.110
Values are presented as mean ± standard deviation.
FIM, Functional Independence Measure; SCIM3, Spinal Cord Independence Measurement III mobility section; BDI, 
Beck Depression Inventory.
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tion of pain after onset, initial number of different medi-
cations, and certain types of medication had significant 
effects on reducing pain medications in patients with 
neuropathic pain with acute and subacute SCI.
Studies on reducing pain medications in SCI are lack-
ing. However, there are studies about the factors of 
prevalence of neuropathic pain [1,5] and epidemiology of 
polypharmacy [21,27]. A previous study [28] reported that 
age at the time of injury is an important factor, associated 
with adaptation to the overall injury and patient’s well-
being. In addition, another study [1,21] suggested that 
age at the time of injury, male sex, and complete injury 
are associated with the onset of neuropathic pain. There-
fore, we predicted that the effect of education would be 
significantly associated with these factors; however, in 
our study, there was no overall difference in the preva-
lence of neuropathic pain between those with neuro-
logical level of injury, sex, and age at the time of injury. 
For elderly or complete SCI patients, secondary health 
conditions are associated with diseases that increase 
polypharmacy [21]. In contrast, though our study differs 
from those that focus only on pain medications, results 
in the age itself are not associated with reduction of pain 
medication. A study conducted by Hanlon et al. [29] 
demonstrated that the effect of education intervention on 
reduction in medications differs, depending on patients’ 
educational level and sex.
Education was found to be effective for patients with a 
recent onset of pain. Compared to patients in the non-
response group, those in the response group had a sig-
nificantly short duration of pain after injury (<60 days). A 
study conducted by van Gorp et al. [5] demonstrated that 
the time after SCI was significantly correlated with the 
prevalence of pain. Besides, Wand et al. [30] demonstrat-
ed that an early educational intervention provided during 
the acute stage showed a more long-term effect on pa-
tients. Therefore, it is important for clinicians to perform 
early and appropriate treatment, as it can prevent neuro-
pathic pain from becoming unnecessarily chronic [30].
Education was effective for patients taking many differ-
ent types of medications. This suggests that prescribing 
multiple medications, does not adequately represent 
patients’ demands. Acetaminophen or NSAIDs, whose 
efficacy for neurogenic pain has barely been verified [31], 
were prescribed to about one-third of patients. Addition-
ally, these medications were medications that we mark-
edly reduced, for use through education. This suggests 
Table 5. Improvement of physical examination function, functional independence status, and depressive mood
Variable
Response group (n=76) Non-response group (n=33)
Initial Follow-up p-value Initial Follow-up p-value
VAS 4.8±2.1 3.4±1.7 <0.001*** 4.8±2.6 3.0±1.7 0.002**
Motor score 44.8±23.2 50.2±24.3 <0.001*** 46.8±26.0 53.1±27.8 0.001**
Sensory score
   Light score 49.9±28.3 54.1±30.4 <0.001*** 52.6±25.4 56.1±24.6 0.049*
   Pin prick score 44.5±29.2 49.5±30.7 0.004** 49.8±26.4 54.5±27.0 0.037*
Functional score
   FIM 59.9±17.9 73.1±23.8 <0.001*** 63.5±20.5 72.2±22.7 <0.001***
   SCIM3 24.6±17.2 36.0±23.5 <0.001*** 29.8±22.6 37.0±26.2 <0.001***
BDI 18.4±7.8 16.8±7.5 <0.001*** 16.8±8.0 16.2±7.2 0.151
Values are presented as mean ± standard deviation.
VAS, visual analogue scale; FIM, Functional Independence Measure; SCIM3, Spinal Cord Independence Measurement 














25 (22.9) 53 (48.6) 25 (22.9)
30 (27.5) 32 (29.4) 25 (22.9) 16 (14.7)
Fig. 2. Change of number of different medications. Values 
are presented as number (%).
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that neuropathic pain is incorrectly diagnosed as muscu-
loskeletal pain, so it does not receive proper treatment. A 
differential diagnosis of neuropathic pain and musculo-
skeletal pain is difficult in patients with an SCI [32]. It is 
important to make an accurate diagnosis and prescribe 
medicine based on a detailed medical history and physi-
cal examination, and to perform regular reviews and 
monitoring. Appropriate treatment includes prescribing 
medications according to patients’ symptoms and con-
sidering the cessation of medications based on regular 
evaluating the drugs’ efficacy. If the patient is already 
taking multiple medications, reviewing the accuracy of 
the diagnosis and effect of the medications, and provid-
ing such information to the patient for feedback may re-
sult in a positive outcome.
Similar results were observed in a study [33] that con-
ducted a face-to-face consultation with the physician; 
additionally, direct involvement of the physician in the 
intervention compared to written recommendations 
achieved a greater reduction in the number of medica-
tions. Furthermore, in our study, we observed that pro-
viding regular education during each medication cycle 
is effective for reducing polypharmacy and subjective 
pain intensities. Although there were no differences in 
the responses to education in accordance with physical 
states and the intensity and characteristics of pain before 
education, patients with reduced polypharmacy after 
education took a high proportion of antidepressants such 
as TCAs and SSRIs for their initial prescriptions, and they 
revealed improvement in depression at follow-up. These 
findings support those of several previous studies, which 
have suggested that depression has a significant correla-
tion with the prevalence of pain and emotional states are 
associated with neuropathic pain [5]. These findings sug-
gest that providing emotional support, would be condu-
cive to the treatment of neuropathic pain in patients with 
an SCI.
This study has some limitations. First, subjects’ so-
cioeconomic statuses, including educational level were 
not assessed. The present study revealed that socioeco-
nomic circumstances and family compositions affect 
neuropathic pain, but they may also have a crucial role, 
as financial hardship is particularly associated with co-
morbidities and pain [34]. It is proven that educational 
level influences the reduction in polypharmacy in elderly 
patients [29], and that educational level is affected by sex. 
Second, we could not subjectively survey patients’ satis-
faction after reducing their medications [14]. According 
to a previous study [1], 70% of patients with an SCI with 
pain responded that pain affected their life significantly. 
Hence, examining the correlation between changes in 
pain caused by a reduction in pain medications and en-
hancements in quality of life, activities of daily living, and 
sleep patterns would have provided more meaningful 
implications. Third, selection bias may have occurred. 
Although we reduced pain medications based on the 
feedback of patients, a physical examination, and the 
results of previous published studies [35,36], the physi-
cians’ subjective opinion could potentially affect results. 
Fourth, further research that considers the dosage and 
number of different medicines taken is needed. Fifth, the 
long-term effects of the intervention in this study were 
not measured, and a comparison with a control group 
was not performed. Pitkala et al. [27] conducted a hospi-
tal-based study, on an intervention to reduce polyphar-
macy in elderly patients for 12 months; they found that 
the number of medications used were significantly re-
duced during in-hospital care monitoring, but this value 
reverted to the baseline value after the patients returned 
home. Further randomized, control studies and long-
term follow-ups are needed to quantify the relationship 
between non-pharmacological methods and pain reduc-
tion outcomes.
Many physicians do not request patients to compile a 
complete list of drugs taken, or they do not review the 
patient’s drug list regularly to evaluate medications that 
could be stopped [37]. Appropriate polypharmacy is not 
just about reducing the number of drugs, as the prescrip-
tion of medication should also be appropriate to the 
patients’ needs [37]. The present study demonstrated 
that rehabilitation specialists can reduce inappropriately 
prescribed drugs and possibly adverse drug effects, due 
to neuropathic pain through pharmaceutical education 
without adversely affecting the health-related quality of 
life of patients with SCI and neuropathic pain. Research-
ers have argued that few treatments have clearly demon-
strated efficacy, particularly with the treatment of neuro-
pathic SCI pain [38]. 
In conclusion, for patients with neuropathic pain, pro-
viding education would be a cost-effective way to reduce 
the side effects of medication and increase patients’ sta-
bility while reducing pain. Hence, reducing the number 
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of medications by effectively implementing education as 
an early intervention for patients and more initial medi-
cation types, may be conducive to the long-term man-
agement of patients.
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